Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
Jacqueline Palace(University of Oxford), Carolina Mainella, Mariana De Virgiliis, Carolina Obregon, Dean M. Wingerchuk(WinnMed), Murat Terzi(Ondokuz Mayıs University), Mariana Ingolotti, Shanthi Viswanathan(Children's Hospital Research Institute of Manitoba), Victòria Fernández, Fátima Pagani Cassará, Achim Berthele, Kaichen Wang(Changchun University of Science and Technology), Carlos Ballario, Luciana Melamud, Viviana Ana Maria Rocchi, Alfredo Laffue, M. Teresa Gutiérrez(Hospital de Basurto), A. E. Stillman(Hospital Kuala Lumpur), Marta Córdoba, Ichiro Nakashima(Tohoku Medical and Pharmaceutical University), N. А. Totolyan, María Fernanda Páez, Kazuo Fujihara(Tohoku University), Anahi Lupinacci, Larisa Miller(Alexion Pharmaceuticals (United States)), Julieta Iourno Danielle, Sean J. Pittock(Mayo Clinic), Celia Oreja‐Guevara, Jorge David Amor, Natalia Larripa(First Pavlov State Medical University of St. Petersburg), Loreley Deborah Teijeiro, Carolina Bocchiardo, Ramon F. Goicoechea, Hernán Gabriel Lattini, Michael Levy(Mass General Brigham), Ho Jin Kim(National Cancer Center), Amy Pace(Alexion Pharmaceuticals (United States)), Alejandra Romano, Jesica Gómez, Hernán Gustavo Gómez, Roberto Martin Perez, Mariana Foa Torres, Florencia Aguirre, Ana Elisa Chiesa, Róisín Armstrong(Pfizer (United States)), Andrés Villa, Josefina Arroyo, Marcus Yountz
Cited by 41
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
|The Lancet|2004|3.2k
Revised diagnostic criteria for neuromyelitis optica
|Neurology|2006|2.6k